Highlights from

ELCC 2019

European Lung Cancer Conference

Geneva 10-13 April 2019

Letter from the editor

Dear Reader

ESMO’s annual European Lung Cancer Congress (ELCC) is a mainly educational event, taking place since it’s launch in April in Geneva.

Once back home, attendees will not have a load of practice-changing studies in their suitcase. They will rather have updated and checked their knowledge of recent evidence and best current practice in the field of lung cancer.

Looking back at the major advances in recent years – in particular due to advances in genetic profiling, imaging, and last but not least: immunotherapy – keeping up is an ever bigger challenge. Helping you to keep up is also our aim, providing you in this Medicom Report with some major summaries of ELCC events (acknowledging in advance that it cannot reflect the totality of the conference).

Wishing you an interesting and educating read,

Yours, sincerely

Stefan Rauh


Dr Stefan Rauh is currently working as haemato-oncologist in the oncology department of Centre Hospitalier Emile Mayrisch, Esch, Luxembourg. He is mainly involved in clinical work but also in research and teaching activities and is interested in public policy and international cooperation projects in oncology. He is Chair of the ESMO Practicing Oncologist’s Working Group since 2015, member of the ESMO Quality Task Force, extended member of the ESMO Public Policy Committee, Assistant Editor of ESMO Cancer Horizons, and has been an ESMO Executive Board member in 2015-2016. He is co-author of the 2017 ESMO European Cancer Patient Coalition (ECPC) Patient Survivorship Guide and an invited expert for the ECPC.

Top image: © Nerthuz

Article image: Medicom

The content and interpretation of these conference highlights are the views and comments of the speakers/authors.